Share
News
-
21 October 2011 /Prices and reimbursement
Decision on general reimbursement for Cholestagel®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Cholestagel®. The product is neither eligible for general nor general conditional reimbursement. Cholestagel® is used for treatment of elevated blood cholesterol levels.
-
12 October 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Bydureon
The Danish Medicines Agency has completed its review of an application for general reimbursement for Bydureon®. The product has been granted general reimbursement. Bydureon® is used for the treatment of type 2 diabetes in adults.
-
07 October 2011 /Prices and reimbursement
Changed reimbursement for medicines for depression and anxiety as of 5 March 2012
With effect from 5 March 2012, the reimbursement is changed for certain medicinal products for treatment of depression and anxiety (antidepressants and anxiolytics). Based on the Reimbursement Committee's recommendation, the Danish Medicines Agency has decided that in future the general rule is that treatment with inexpensive medicines (e.g. sertraline and citalopram) must be attempted before reimbursement can be granted for more expensive medicines (e.g. escitalopram, duloxetine, pregabalin and agomelatine).
-
04 October 2011 /Prices and reimbursement
The reimbursement for glucosamine is removed on 28 November 2011
The Reimbursement Committee and the Danish Medicines Agency have reassessed the reimbursement status of glucosamine-containing medicines. We have decided to remove the reimbursement for these over-the-counter medicines on 28 November 2011. Glucosamine is used for the alleviation of painful osteoarthritis.
